For research use only. Not for therapeutic Use.
Lacutamab（Cat No.:I042224）is a monoclonal antibody that targets the CD47 protein, which is commonly overexpressed on cancer cells and acts as a “don’t eat me” signal to evade immune detection. By binding to CD47, Lacutamab enhances the immune system’s ability to recognize and destroy cancer cells, particularly in hematologic cancers like leukemia and lymphoma. It is being studied for its potential in treating solid tumors and hematologic malignancies, either as a monotherapy or in combination with other treatments. Clinical trials are ongoing to assess Lacutamab’s safety, efficacy, and its role in cancer immunotherapy.
| Catalog Number | I042224 |
| CAS Number | 2187368-16-5 |
| Purity | ≥95% |
